En desventaja frente a Europa: los pacientes españoles con migraña tienen un acceso limitado a los tratamientos más nuevos y eficaces

Spanish migraine patients face a significant disadvantage compared to the rest of Europe regarding access to newer and more effective treatments. While the European Medicines Agency (EMA) approves the use of anti-CGRP medications for individuals suffering from migraines more than four days a month, access to these therapies remains limited in Spain.